Analysts See $-0.09 EPS for AC Immune SA (ACIU)

February 24, 2018 - By Michael Collier

 Analysts See $ 0.09 EPS for AC Immune SA (ACIU)

Analysts expect AC Immune SA (NASDAQ:ACIU) to report $-0.09 EPS on March, 16.After having $-0.16 EPS previously, AC Immune SA’s analysts see -43.75 % EPS growth. The stock increased 0.74% or $0.08 during the last trading session, reaching $10.9. About 40,353 shares traded. AC Immune SA (NASDAQ:ACIU) has 0.00% since February 24, 2017 and is . It has underperformed by 16.70% the S&P500.

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops therapeutic and diagnostic products for prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The company has market cap of $620.45 million. The Company’s SupraAntigen and Morphomer platforms generates antibodies and small molecules that selectively bind to misfolded proteins to address neurodegenerative indications, such as Alzheimer's , Parkinson's, down syndrome, and glaucoma diseases. It currently has negative earnings. The company's lead product candidate is crenezumab, a humanized, monoclonal, and conformation-specific anti-Abeta antibody, which is in Phase 3 clinical studies.

More notable recent AC Immune SA (NASDAQ:ACIU) news were published by: which released: “AC Immune files for US IPO to develop Alzheimer’s drug” on May 31, 2016, also with their article: “AC IMMUNE REPORTS FULL YEAR 2016 FINANCIAL RESULTS AND R&D UPDATE” published on March 17, 2017, published: “AC IMMUNE APPOINTS EXPERIENCED LIFE SCIENCE PROFESSIONAL AS NEW CHIEF …” on November 23, 2016. More interesting news about AC Immune SA (NASDAQ:ACIU) were released by: and their article: “News AC Immune SAACIU” published on June 03, 2016 as well as‘s news article titled: “AC IMMUNE PARTNER GENENTECH PRESENTS IMPORTANT DATA ON ALZHEIMER’S THERAPY …” with publication date: December 09, 2016.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter: